NRG Oncology NRG-GY018 Study Demonstrates Significantly Improved Progression Free Survival Outcomes for Women with Advanced or Recurrent Endometrial Cancer with the Addition of Pembrolizumab to Chemotherapy

February 03 2023NRG Oncology Phase III clinical trial, NRG-GY018, evaluating pembrolizumab in combination with standard of care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression free survival (PFS) for the treatment of patients with stage III-IV or recurrent endometrial carcinoma, regardless of mismatch repair status. A pre-specified interim analysis, conducted by…

Read the full article here

Source: NRG

Categories: Hem/Oncs, Latest Headlines

Tweets with this article

Hal Burstein, MD

The beat goes on for pembrolizumab now with activity in endometrial cancer, regardless of mismatch repair status. https://t.co/6qR5MTpE6x

Related Articles

The 150 Most Influential Bostonians in 2024

Love ’em or hate ’em, these rankings are sure to stir the pot.

Hal Burstein, MD May 2, 2024

The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype

At a recent Oncologic Drugs Advisory Committee (ODAC) Meeting, the U.S. Food and Drug Administration (FDA) laid out its rationale for rejecting the supplem

Hal Burstein, MD April 30, 2024

Is Your Cancer Test Accurate? The FDA Wants to Make Sure

A new rule details how the agency will oversee the $10 billion industry for medical tests conducted by single laboratories.

Hal Burstein, MD April 30, 2024

Are we all one overhead bin battle away from an in-flight meltdown? – The Boston Globe

Maybe we should accept reality — this is who we are — and play to our strengths.

Hal Burstein, MD April 22, 2024

Opinion | ‘What’s My Life Worth?’ The Big Business of Denying Medical Care

Insurance companies have weaponized a seemingly benign process to protect their profits, and it’s putting patients at risk.

Hal Burstein, MD April 12, 2024

Is That A.I. Mammogram Worth the Cost? (Gift Article)

The new add-on service for breast exams can cost between $40 and $100. We asked experts to separate the sales pitch from the science.

Hal Burstein, MD April 8, 2024

Opinion | ‘What’s My Life Worth?’ The Big Business of Denying Medical Care

Insurance companies have weaponized a seemingly benign process to protect their profits, and it’s putting patients at risk.

Hal Burstein, MD April 2, 2024

Opinion | ‘What’s My Life Worth?’ The Big Business of Denying Medical Care

Insurance companies have weaponized a seemingly benign process to protect their profits, and it’s putting patients at risk.

Hal Burstein, MD March 27, 2024

Opinion | ‘What’s My Life Worth?’ The Big Business of Denying Medical Care

Insurance companies have weaponized a seemingly benign process to protect their profits, and it’s putting patients at risk.

Hal Burstein, MD March 20, 2024

Companies paid top executives more than they paid in US taxes – report

Compensation for senior bosses at firms from Tesla to T-Mobile US worth more than those companies’ net tax payments, study finds

Hal Burstein, MD March 16, 2024